Related Experiment Video

Updated: Feb 5, 2026

Comparing Eye-tracking Data of Children with High-functioning ASD, Comorbid ADHD, and of a Control Watching Social Videos
05:32

Comparing Eye-tracking Data of Children with High-functioning ASD, Comorbid ADHD, and of a Control Watching Social Videos

Published on: December 7, 2018

9.7K

Evaluation of Two Types of Drug Treatment with QEEG in Children with ADHD

Ramazan Aldemir1, Esra Demirci2, Ayşe Kaçar Bayram3

  • 1Biomedical Device Technology Program, Erciyes University, Kayseri, Turkey.

Translational Neuroscience
|September 8, 2018
PubMed

Insights

Methylphenidate and atomoxetine treatments showed similar effects on electroencephalography (EEG) signals in children with Attention Deficit and Hyperactivity Disorder (ADHD). Atomoxetine demonstrated more significant quantitative EEG changes in frontal regions compared to methylphenidate.

Area of Science:

  • Neuroscience
  • Pediatric Psychiatry
  • Pharmacology

Background:

  • Attention Deficit and Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder in children.
  • Pharmacological interventions, including methylphenidate and atomoxetine, are primary treatments for ADHD.
  • Electroencephalography (EEG) and Quantitative EEG (QEEG) offer insights into brain activity and treatment effects.

Purpose of the Study:

  • To evaluate the impact of methylphenidate and atomoxetine on EEG signals in children with ADHD.
  • To compare the QEEG changes induced by these two ADHD medications.
  • To explore the potential of QEEG in supporting ADHD diagnosis and treatment monitoring.

Main Methods:

  • Forty children (7-17 years) were divided into an ADHD group (n=20) and a control group (n=20).
  • The ADHD group was further split into methylphenidate (MPH) and atomoxetine (ATX) treatment subgroups (n=10 each).
  • EEG data were recorded before and after 3 months of treatment, analyzing power spectrum densities in delta, theta, alpha, and beta bands.

Main Results:

  • Both methylphenidate and atomoxetine treatments yielded similar findings across EEG power spectrum densities (delta, theta, alpha, beta bands).
  • Statistically significant EEG amplitude variations were observed, primarily in the frontal and temporal regions for both medications.
  • No significant differences in overall EEG power spectrum densities were noted between MPH and ATX treatments.

Conclusions:

  • Quantitative EEG (QEEG) rates at frontal electrodes showed statistically greater significance after atomoxetine treatment compared to methylphenidate.
  • This suggests potential differential effects of atomoxetine on frontal brain activity in ADHD.
  • The study highlights QEEG's potential role in assessing treatment response and possibly correlating with ADHD severity.
Abstract

Keywords:
Attention-deficit hyperactivity disorder (ADHD)QEEGdrug treatmentnon-stimulantsstimulants

More Related Videos

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.6K
Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol13:09

Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol

Published on: April 1, 2018

11.0K

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
306
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
849
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
524
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
722
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.7K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
514